Uniqure NV (QURE NASDAQ) stock market data APIs
$14.3177
-0(-0%)
as of July 7, 2025
Try our APIs with
free plan!
Uniqure NV Financial Data Overview
Price chart is built with
Anychart
uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases in the United States. The company offers HEMGENIX that allows people living with hemophilia B to produce factor IX, which can lower the risk of bleeding. Its lead product candidate is AMT-130, a gene therapy candidate, which is in Phase I/II clinical study for the treatment of Huntington's disease. The company also develops AMT-260, which is in Phase I/IIa clinical trial for the treatment of mesial temporal lobe epilepsy; AMT-162, which is in Phase I/IIa clinical trial to treat superoxide dismutase enzyme-amyotrophic lateral sclerosis; and AMT-191, an investigational gene therapy candidate which is in phase I/IIa clinical trial for the treatment of fabry disease. It has a licensing agreement with Apic Bio to develop, manufacture, and commercialize intrathecally administered investigational gene therapy for ALS caused by mutations in SOD-1; and development and commercial supply agreement with CLS Bhering. uniQure N.V. was founded in 1998 and is headquartered in Amsterdam, the Netherlands.
Prev. Close
14.3177
Open
14.3156
High
14.379
Low
13.9887
52 wk Range
4.45-19.18
Market Cap
789 M
Shares Outstanding
54 749 K
Revenue
20 201 K
EPS
-0.7278
Beta
0.09
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Uniqure NV data using free add-ons & libraries
Get Uniqure NV Fundamental Data
Uniqure NV Fundamental data includes:
- Net Revenue: 20 201 K
- EBITDA: -157 584 000
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-06-18
- EPS/Forecast: -0.8863
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Uniqure NV News
New
Lake Street: AMT-130 Could Be Game-Changer For ClearPoint
uniQure N.V. (NASDAQ:QURE) is among the 11 Best Genomics Stocks to Buy According to Hedge Funds. Lake Street Capital reiterated its Buy rating and $30 price target for ClearPoint following uniQure N.V...
uniQure N.V. chief legal officer Potts sells $70k in shares
uniQure N.V. (NASDAQ:QURE) Chief Legal Officer Jeannette Potts sold 4,670 ordinary shares of the company on June 16, 2025, according to a Form 4 filing with the Securities and Exchange Commission. The...
Insider Sale: Chief Legal Officer of $QURE Sells 4,670 Shares
Jeannette Potts, the Chief Legal Officer of $QURE, sold 4,670 shares of the company on 06-16-2025 for an estimated $70,703. We received data on the trade from a recent SEC filing. This was a sale of a...
uniQure Announces Appointment of Kylie O’Keefe as Chief Customer and Strategy Officer
~ Proven biotech executive to lead commercialization of AMT-130 in Huntington’s disease ~ LEXINGTON, Mass. and AMSTERDAM, June 11, 2025 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
